XML 67 R28.htm IDEA: XBRL DOCUMENT v3.21.1
Income Tax
12 Months Ended
Dec. 31, 2020
Text Block [Abstract]  
Income Tax
22.
Income Tax
For the year ended December 31, 2020, 2019 and 2018, the Group generated losses in both Germany and the U.S.
During 2020, 2019 and 2018, the Group’s German operations were subject to a statutory tax rate of 29.1%. In the U.S., the Group was subject to a corporate income tax rate of 21% for the year ended December 31, 2020, 2019 and 2018.
 
As of December 31, 2020, 2019 and 2018, no deferred tax assets have been recognized in respect of these losses, due to the uncertainty of the Group’s ability to generate taxable profits in the foreseeable future. The current assessment regarding the usability of deferred tax assets may change, depending on the Group’s taxable income in future years. This may result in higher or lower deferred tax assets related to tax losses carried forward. Due to the ARYA Merger described in Note 3, there are certain limitations on tax losses carried forward for net operating losses incurred by Immatics US, Inc., under Section 382 of the U.S. Internal Revenue Code.
A reconciliation between taxes on income reflected on the Consolidated Statement of Loss and the expected income tax benefit, based on the Group’s German statutory tax rate, for the years ended December 31, 2020, 2019 and 2018 is as follows:
 
   
Year ended December 31,
 
   
2020
   
2019
   
2018
 
   
(Euros in thousands)
 
Loss before tax
   (229,616   (32,487   (32,355
Expected tax benefit
   66,818    9,454    9,415 
Effects
               
Difference in tax rates
   (2,582   (1,875   (1,373
Non-deductible  tax-expenses
   (599   (61   (70
Government grants exempted from taxes
   45    8    853 
Permanent Differences
   (44,461   —      —   
Non-recognition of deferred taxes on tax losses and temporary differences
 
 (19,221   (7,526   (8,825
   
 
 
   
 
 
   
 
 
 
Taxes on income
   —      —      —   
   
 
 
   
 
 
   
 
 
 
The main permanent difference relates to the Share listing expense of €153 million, which does not have a corresponding taxable expense. Other permanent differences include transaction cost directly attributable and incremental to capital raises and expenses for equity-settled share-based compensation.
Deferred tax assets consist of the following:
 
 
  
As of
 
 
  
December 31, 2020
 
 
December 31, 2019
 
 
  
(Euros in thousands)
 
 
  
Deferred
tax
assets
 
 
Deferred
tax
liabilities
 
 
Deferred
tax
assets
 
 
Deferred
tax
liabilities
 
Intangible assets
   1,770         2,064      
Right-of-use
asset
        (1,713        (854
Deferred revenue
   180         358      
Other liabilities
             607      
Lease liability
   1,776         886      
Deferred expenses
   3         14      
Recognized
   3,729    (1,713   3,929    (854
Netting
   (1,713   1,713    (854   854 
Non-recognition
due to history of losses
   (2,016        (3,075     
   
 
 
   
 
 
   
 
 
   
 
 
 
Net tax
  
—  
   
—  
   
—  
   
—  
 
   
 
 
   
 
 
   
 
 
   
 
 
 
 
As of December 31, 2020, and 2019, the Group had accumulated tax losses of €288 million and €219 million,
respectively, that may be offset against future taxable profits of the Group subject to certain limitations.
As of December 31, 2020, €26 million of total tax losses is subject to a twenty-year carryforward period. All other tax losses have an indefinite carryforward period.
The Group has limited taxable temporary differences and no tax planning opportunities available that could partly support the recognition of these losses as deferred tax assets. On this basis, the Group has determined that it cannot recognize deferred tax assets on the tax losses carried forward as well as on temporary differences.
Limitation on tax loss carryforwards in the US Inc. is 80.00% starting with losses generated after January 1, 2018. These have an indefinite carryforward period, but no carryback option. Any losses generated prior to January 1, 2018 still can be utilized at 100.00%
and are subject to a twenty-year carry forward expiration period. Due to the ARYA Merger described in Note 3, there are certain limitations on tax losses carried forward for net operating losses incurred by Immatics US, Inc., under Section 382 of the U.S. Internal Revenue Code. For Immatics Biotechnologies GmbH, we believe that the ARYA Merger did not lead to a forfeiture of tax losses carried forward in accordance with § 8c KStG.
Deferred tax assets have not been recognized in respect of these losses due to the uncertainty of the Group’s ability to generate taxable profits in the foreseeable future. The current assessment regarding the usability of deferred tax assets may change depending on the income situation of future years and may result in higher deferred tax assets on net tax losses carried forward.